admin

Johnson & Johnson Innovation – JLABS @ Washington, DC: We did it! Persevering through a time of great challenge and change, today we’re happy to share that we’ve opened our doors in a thriving ecosystem, to entrepreneurs, early-stage companies and the life sciences community.

BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pre-clinical data from its GBA1 Parkinson’s disease program. The findings were highlighted in a presentation at the XXVI International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, a research conference dedicated to Parkinson’s disease and other disorders affecting muscle tone and motor control, being held virtually May 1-4, 2021.

Women Building Bio 2021 is just around the corner.

Save the date for September 30th to join our 6th year of Women Building Bio. An event always focused on advancing the bioscience through collaboration between industry and academia, researchers and innovators, professionals and decision-makers.

On a first-quarter earnings call Thursday, Emergent’s CEO addressed a turbulent month for the Gaithersburg biopharmaceutical company.

Image: https://www.bizjournals.com

Locally Researched by: Carolyn M. Proctor, Washington Business Journal Apr 30, 2021, 6:00am EDT

Source: The companies, Form 990s, SEC filings and regional economic development agencies

Around Baltimore, folks tend to analyze economic trends through three vantage points: the city, the region and the state. No matter which level you’re looking at, data on venture capital shows that the first quarter of 2021 brought an influx of investment for local emerging companies.

Data from the latest MoneyTree report by PwC/CB Insights shows that Maryland companies received a collective $562 million in investment over 24 deals. It was a nearly 68% increase in the number of dollars and a 26% increase in the number of deals from the fourth quarter of 2020, which capped off a big year of investment in the pandemic.

Image: nsightin Health’s team in the South Baltimore office. (Courtesy photo)

A potential vaccine has brought new life to the embattled Gaithersburg biotech.

Image: Novavax CEO Stanley Erck, left, and Gregory Glenn, head of research and development, at Novavax’s office in Gaithersburg. EMAN MOHAMMED

Oxford, UK – Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $110.5 million. All ADSs sold in the offering are being offered by Vaccitech. The ADSs are expected to begin trading on The Nasdaq Global Market on April 30, 2021 under the ticker symbol “VACC.”  In addition, Vaccitech has granted the underwriters a 30-day option to purchase up to an additional 975,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2021, subject to satisfaction of customary closing conditions.

Gain Therapeutics CEO Eric Richman joins BioTalk to Discuss His Career, Redefining Drug Discovery, and Ventures in the BioHealth Capital Region and Beyond.

Listen now on Apple https://apple.co/3vB8mS3, Google https://bit.ly/2QI3xrb, Spotify https://spoti.fi/33021mT, and TuneIn https://bit.ly/2S7Yuk4.